Crysvita: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Burosumab

Indications/Uses

X-linked hypophosphatemia in adult & ped patients ≥1 yr.

Dosage/Direction for Use

SC Max vol: 1.5 mL/inj. Adult ≥18 yr 1 mg/kg rounded to the nearest 10 mg up to a max dose of 90 mg, administered every 4 wk. Ped patient 1 to <18 yr Initially 0.8 mg/kg rounded to the nearest 10 mg, administered every 2 wk up to a max dose of 90 mg.

Contraindications

Concomitant use w/ oral phosphate &/or active vit D analogs (eg, calcitriol, paricalcitol, doxercalciferol, calcifediol). When serum P is w/in or above the normal range for age. Severe renal impairment or ESRD.

MIMS Class

Other Drugs Acting on Musculo-Skeletal System

ATC Classification

M05BX05 - burosumab ; Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.

Regulatory Classification

POM

Presentation/Packing

Form

Crysvita soln for inj 10 mg/mL

Packing/Price

1's

Form

Crysvita soln for inj 20 mg/mL

Packing/Price

1's

Form

Crysvita soln for inj 30 mg/mL

Packing/Price

1's

Crysvita

burosumab

Manufacturer:

Kyowa Kirin